Given a passage, construct a question on the basis of the information present in the passage. Construct the question in such a way that (i) it is unambiguous, (ii) it is answerable from the passage, (iii) its answer is unique (iv) it answer uses text phrases from the passage. Avoid creating questions that (i) can't be answered correctly without actually understanding the passage and (ii) uses the same words or phrases given in the passage.

In mice, the farnesoid X receptor is involved in bacterial translocation, which can result in spontaneous bacterial peritonitis in patients with cirrhosis. We investigated if polymorphisms in the farnesoid X receptor gene influence the risk for spontaneous bacterial peritonitis.', 'Laboratory and clinical data of 293 cirrhotic patients with ascites and 226 healthy controls were prospectively collected. The rs56163822, rs11110390 and rs12313471 polymorphisms of the farnesoid X receptor were determined.', '115 (39%) patients had spontaneous bacterial peritonitis. Distribution of all farnesoid X receptor genotypes matched the Hardy-Weinberg equilibrium. Patients with spontaneous bacterial peritonitis had a higher frequency of the rs56163822 GT genotype (7.0%) than patients without (1.7%, OR=4.4, p=0.02). This genotype was confirmed as predictor of spontaneous bacterial peritonitis by binary logistic regression analysis (OR=6.8, p=0.018).
Does a farnesoid X receptor polymorphism predispose to spontaneous bacterial peritonitis?

Genetic variability in hepatic uptake was recently shown to influence the disposition and cholesterol-lowering effects of statins. Ezetimibe, an inhibitor of the intestinal cholesterol uptake protein Niemann-Pick C 1 like 1, is another drug for which genetic polymorphisms of hepatic organic anion transporting polypeptides (OATPs) are expected to be of clinical relevance because ezetimibe undergoes intensive enterohepatic circulation for which hepatic uptake transporters may be rate-limiting determinants.', 'Using OATP1B3-, OATP2B1-, and OATP1B1-transfected HEK cells, including the OATP1B1 variants OATP1B1*1b and OATP1B1*5, we measured the uptake of ezetimibe and its glucuronide and we analyzed the competition with the common OATP-substrate bromosulfophthalein. Disposition and sterol-lowering effects of 20-mg ezetimibe were measured in 35 healthy participants genotyped for OATP1B1, ABCB1, ABCC2, and UGT1A1.', 'Ezetimibe glucuronide inhibited bromosulfophthalein uptake in all OATP-transfected cells (50% inhibitory concentration (IC50): 0.14-0.26 mumol/l) whereas ezetimibe was 30-100 times less potent. Only the glucuronide was accumulated significantly in cells expressing OATP1B1 and OATP2B1. Its uptake in cells expressing OATP1B1*1b and *5 was reduced. In-vivo studies showed there was a gene-dose-dependent decrease in the area under the curve of ezetimibe in participants with the OATP1B1*1b protein (*1a/*1a, N=12, 112+/-66 ngxh/ml vs. *1a/*1b, N=8, 88+/-39 ngxh/ml vs. *1b/*1b, N=5, 55+/-18 ngxh/ml; Jonkheere-Terpstra, P=0.041) and a tendency for increased glucuronide exposure (704+/-296 vs. 878+/-369 vs. 1059+/-363 ngxh/ml; P=0.092). Fecal ezetimibe excretion was significantly decreased whereas renal glucuronide excretion was increased in carriers of *1b/*1b. Fecal excretion was also diminished in carriers of OATP1B1*5 and *15. The sterol-lowering effect of ezetimibe was not influenced by OATP1B1 polymorphisms.
Is disposition of ezetimibe influenced by polymorphisms of the hepatic uptake carrier OATP1B1?

To determine the effects of co-ingesting caffeine (CAF) and carbohydrate (CHO) on high-intensity intermittent sprints (HIS) performance and physiological responses.', 'Twelve active males underwent 4 interventions at least 7days apart in a randomized, double-blind, placebo-controlled, balanced trial. A meal contained 65% CHO was provided 2h before the HIS test. Participants ingested the placebo (PLA) or CAF (6mgkg(-1) BW) 1h before taking an HIS test, and ingested a PLA or CHO solution (0.8gkg(-1)BW) before undergoing the testing protocol. The HIS protocol comprised ten sets of 54-s sprints on a cycle ergometer with a 2-min recovery between each set.', 'There was no significant difference between peak power output and mean power output between trials (p>0.05). Compared with PLA, CAF+CHO resulted in a 5.2% reduction in total work, corresponding to a 24.7-25.7% increase in fatigue at the end stage of the HIS. The administration of CAF+CHO supplementation also resulted in an 11.1% increase in blood lactate, and elevated blood glucose concentrations throughout HIS testing compared with PLA (p<0.05). Cortisol concentrations also increased with CAF+CHO intake compared with PLA; however, there was no significant effect of CAF+CHO supplementation on testosterone concentrations.
Does co-ingestion of caffeine and carbohydrate after meal improve performance at high-intensity intermittent sprints with short recovery times?